AU2021218708B2 - Exogenous nitric oxide for improved susceptibility and lowered antibiotic resistance in resistant respiratory bacteria - Google Patents

Exogenous nitric oxide for improved susceptibility and lowered antibiotic resistance in resistant respiratory bacteria Download PDF

Info

Publication number
AU2021218708B2
AU2021218708B2 AU2021218708A AU2021218708A AU2021218708B2 AU 2021218708 B2 AU2021218708 B2 AU 2021218708B2 AU 2021218708 A AU2021218708 A AU 2021218708A AU 2021218708 A AU2021218708 A AU 2021218708A AU 2021218708 B2 AU2021218708 B2 AU 2021218708B2
Authority
AU
Australia
Prior art keywords
cos
antibiotic
nitric oxide
microorganism
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021218708A
Other languages
English (en)
Other versions
AU2021218708A1 (en
Inventor
Kaitlyn Rose ROUILLARD
Mark H. Schoenfisch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of AU2021218708A1 publication Critical patent/AU2021218708A1/en
Application granted granted Critical
Publication of AU2021218708B2 publication Critical patent/AU2021218708B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Medicinal Preparation (AREA)
AU2021218708A 2020-02-14 2021-02-11 Exogenous nitric oxide for improved susceptibility and lowered antibiotic resistance in resistant respiratory bacteria Active AU2021218708B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062976738P 2020-02-14 2020-02-14
US62/976,738 2020-02-14
US202063125865P 2020-12-15 2020-12-15
US63/125,865 2020-12-15
PCT/US2021/017711 WO2021163367A1 (en) 2020-02-14 2021-02-11 Exogenous nitric oxide for improved susceptibility and lowered antibiotic resistance in resistant respiratory bacteria

Publications (2)

Publication Number Publication Date
AU2021218708A1 AU2021218708A1 (en) 2022-09-29
AU2021218708B2 true AU2021218708B2 (en) 2024-10-03

Family

ID=77292649

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021218708A Active AU2021218708B2 (en) 2020-02-14 2021-02-11 Exogenous nitric oxide for improved susceptibility and lowered antibiotic resistance in resistant respiratory bacteria

Country Status (6)

Country Link
US (1) US20230082968A1 (https=)
EP (1) EP4103199A4 (https=)
JP (1) JP2023513750A (https=)
CN (1) CN115209905A (https=)
AU (1) AU2021218708B2 (https=)
WO (1) WO2021163367A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114191559A (zh) * 2021-11-04 2022-03-18 陕西省微生物研究所 一种no增强抗生素抗菌敏感性的方法及应用
CN119789870A (zh) * 2022-06-08 2025-04-08 诺欧生物有限责任公司 含有一氧化氮释放化合物的多组分药物组合物和试剂盒及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125262A1 (en) * 2005-05-24 2006-11-30 Environmental Biotechnology Crc Pty Limited Methods and compositions for regulating biofilm development
US8399005B2 (en) * 2007-10-12 2013-03-19 University Of North Carolina At Chapel Hill Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents
EP2885323B1 (en) * 2012-08-17 2023-08-30 The University of North Carolina At Chapel Hill Water soluble nitric oxide-releasing polyglucosamines and uses thereof

Also Published As

Publication number Publication date
US20230082968A1 (en) 2023-03-16
AU2021218708A1 (en) 2022-09-29
EP4103199A1 (en) 2022-12-21
JP2023513750A (ja) 2023-04-03
EP4103199A4 (en) 2024-04-03
CN115209905A (zh) 2022-10-18
WO2021163367A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
Rouillard et al. Exogenous nitric oxide improves antibiotic susceptibility in resistant bacteria
Hawas et al. Combination therapies for biofilm inhibition and eradication: a comparative review of laboratory and preclinical studies
Nabawy et al. Dual antimicrobial-loaded biodegradable nanoemulsions for synergistic treatment of wound biofilms
Mohamed et al. Targeting biofilms and persisters of ESKAPE pathogens with P14KanS, a kanamycin peptide conjugate
Rakesh et al. Promising bactericidal approach of dihydrazone analogues against bio-film forming Gram-negative bacteria and molecular mechanistic studies
Nakonieczna et al. Rose bengal-mediated photoinactivation of multidrug resistant Pseudomonas aeruginosa is enhanced in the presence of antimicrobial peptides
AU2021218708B2 (en) Exogenous nitric oxide for improved susceptibility and lowered antibiotic resistance in resistant respiratory bacteria
ES2690725T3 (es) Composiciones que comprenden cefepima y tazobactam
CA3171167A1 (en) Exogenous nitric oxide for improved susceptibility and lowered antibiotic resistance in resistant respiratory bacteria
Huang et al. Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
CN111362834B (zh) 一种具有抗耐药性的抗菌脒类低聚物及其制作方法和用途
US20210290648A1 (en) Potentiation of B-Lactam Antibiotics and B-Lactam/B-Lactamase Inhibitor Combinations Against Multidrug and Extensively Drug-Resistant Pseudomonas Aeruginosa Using Non-Ribosomal Tobramycin-Cyclam Conjugates
Cao et al. Antimicrobial activity and mechanism of action of Nu-3, a protonated modified nucleotide
Bhowmik et al. Successfully treating biofilms of extensively drug resistant Klebsiella pneumoniae isolates from hospital patients with N-Acetyl Cysteine
JP2016535038A (ja) 抗菌剤を含む医薬品組成物
KR20160072254A (ko) 항균제를 포함하는 제약학적 조성물
Lv et al. Expanded applications of omeprazole: Synergistic reversal of colistin resistance in Acinetobacter baumannii
US20240325341A1 (en) Anti-bacterial effect of halogenated fluoresceins against colistin-resistant gram-negative bacteria
Ayad Al-Tawee et al. The combined impact of chlorhexidine digluconate and chitosan as microbicide agents against the prevailing MDR Pseudomonas aeruginosa isolates from Iraqi patients: An in vitro study.
Rouillard Characterization of Pseudomonas aeruginosa Susceptibility to Nitric Oxide and Antibiotics Under Cystic Fibrosis-Relevant Conditions
Chirra Novel Antimicrobials and Drug Delivery Devices to Treat Multidrug Resistant Infections
Wang et al. Synergistic Antibacterial Effects of Ceftazidime/Avibactam and Auranofin Combination against Carbapenem-Resistant Klebsiella pneumoniae: In Vitro and in Vivo Evaluation
Nguyen Examining the Impact of Nitric Oxide on Bacterial Physiology in Complex Biological Environments
EP4731185A1 (en) Drug product and related methods
EP4518856A1 (en) Use of zinc porphyrin as an antimicrobial

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)